| Molecular Formula | C21H19F2N5O |
| Molar Mass | 395.41 |
| Density | 1.364±0.06 g/cm3(Predicted) |
| Solubility | Soluble in DMSO (>25 mg/ml) |
| Appearance | Form solid, color Pale yellow |
| Color | Pale yellow |
| pKa | 13?+-.0.40(Predicted) |
| Storage Condition | -20°C |
| Stability | Stable for 2 years from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months. |
| Physical and Chemical Properties | Bioactive PLX5622 is a highly selective CSF-1R inhibitor with IC50 less than 10 nM, and its selectivity for CSF-1R is more than 20 times higher than that of KIT and FLT3. |
| Use | The application PLX5622 is a highly selective, effective oral CSF1R inhibitor that can penetrate the blood-brain barrier with a Ki value of 5.9 nM, which can be used for the elimination of expanded and specific microglia before and during the development of the disease course. PLX5622 has good pharmacological properties. |
| In vivo study | In mice, rats, dogs, and monkeys, PLX5622 has ideal pharmacokinetic properties with brain permeability of about 20%. PLX5622 had low systemic clearance, moderate volume of distribution, and good oral bioavailability (>30%). It is an effective tool to study the dynamics of microglia. PLX5622 can cause the elimination of persistent, specific microglial cells during or prior to the development of Alzheimer's disease pathology. |
| 1mg | 5mg | 10mg | |
|---|---|---|---|
| 1 mM | 2.529 ml | 12.645 ml | 25.29 ml |
| 5 mM | 0.506 ml | 2.529 ml | 5.058 ml |
| 10 mM | 0.253 ml | 1.265 ml | 2.529 ml |
| 5 mM | 0.051 ml | 0.253 ml | 0.506 ml |
| Solubility | Soluble in DMSO (>25 mg/ml) |